Ascletis Pharma Inc Cash Flow Conversion Efficiency
Ascletis Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has a cash flow conversion efficiency ratio of -0.013x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-33.98 Million ≈ $-39.73 Million USD) by net assets (€2.57 Billion ≈ $3.00 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ascletis Pharma Inc (2016–2025)
Cash flow conversion efficiency of Ascletis Pharma Inc from 2016 to 2025. This chart illustrates how Ascletis Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ascletis Pharma Inc stock price for real-time trading data and today's change.
Ascletis Pharma Inc Cash Flow Conversion Ratio Explained
Ascletis Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ascletis Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascletis Pharma Inc ranked by their cash flow conversion efficiency. Also see market cap of Ascletis Pharma Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Just Dial Limited
NSE:JUSTDIAL
|
0.023x |
|
Performant Healthcare, Inc
NASDAQ:PHLT
|
0.005x |
|
Tianjin Jiuri New Materials Co Ltd
SHG:688199
|
0.022x |
|
Ooh!Media Ltd
AU:OML
|
0.148x |
|
ChemPartner PharmaTech Co Ltd
SHE:300149
|
0.022x |
|
Arafura Rare EARTHS Ltd
AU:ARU
|
-0.007x |
|
Forge Global Holdings Inc
NYSE:FRGE
|
-0.055x |
|
ESGL Holdings Limited
NASDAQ:OIO
|
-0.041x |
Annual Cash Flow Conversion Efficiency for Ascletis Pharma Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Ascletis Pharma Inc from 2016 to 2025. Review Ascletis Pharma Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.93 Billion ≈ $2.26 Billion |
€-416.78 Million ≈ $-487.25 Million |
-0.215x | -24.03% |
| 2024-12-31 | €1.97 Billion ≈ $2.30 Billion |
€-341.58 Million ≈ $-399.34 Million |
-0.174x | -81.81% |
| 2023-12-31 | €2.34 Billion ≈ $2.74 Billion |
€-223.79 Million ≈ $-261.64 Million |
-0.096x | -70.37% |
| 2022-12-31 | €2.54 Billion ≈ $2.97 Billion |
€-142.45 Million ≈ $-166.54 Million |
-0.056x | -4.17% |
| 2021-12-31 | €2.73 Billion ≈ $3.19 Billion |
€-146.93 Million ≈ $-171.78 Million |
-0.054x | -89.06% |
| 2020-12-31 | €2.98 Billion ≈ $3.49 Billion |
€-84.91 Million ≈ $-99.27 Million |
-0.028x | -27.34% |
| 2019-12-31 | €3.32 Billion ≈ $3.89 Billion |
€-74.34 Million ≈ $-86.91 Million |
-0.022x | +20.65% |
| 2018-12-31 | €3.43 Billion ≈ $4.01 Billion |
€-96.59 Million ≈ $-112.92 Million |
-0.028x | +87.62% |
| 2017-12-31 | €869.83 Million ≈ $1.02 Billion |
€-198.06 Million ≈ $-231.55 Million |
-0.228x | -645.29% |
| 2016-12-31 | €409.08 Million ≈ $478.26 Million |
€-12.50 Million ≈ $-14.61 Million |
-0.031x | -- |
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more